Loading
H&
Hims & Hers Health, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 14 Nov 2024.
Hims & Hers Health, Inc.: what insiders have been doing
Hims & Hers Health, Inc., classified in the Healthcare & Pharma sector, is a listed company based in United States, founded in 2017. Its insiders report their share dealings to SEC (Form 4). Between 18 October 2025 and 18 October 2026, 23 insiders published 123 filings.
The flow runs one way only: 29 sales worth €9.4M, from 8 insiders, and no purchase. The totals do not cover 4 filings with an undisclosed amount. Chi Michael filed the largest sale, €2.1M, on 18 March 2026, which represents 0.038% of the company's market value.
Across the 5,812 companies tracked on its exchange, the median is 19 filings; at 123 filings, this issuer sits above that mark. Since 2021, the database holds 8 purchases and 173 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 2.35 bn USD and net income of 128.4 m USD.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
627
Thresholds
n/a
Buy Volume
€4M
8 ops. · all time
Sell Volume
€81M
173 ops. · all time
Who traded when
BuySaleBoughton Soleil28 sales
Okupe Oluyemi18 sales
Andrew Dudum11 sales
Irene Becklund10 sales
Chi Michael6 sales
Patrick Harrison Carroll6 sales
+6 other insiders
Since the insiders bought
- +84.2%Entry US$19.32 · Close at T+365 US$35.58
- +246.4%Entry US$15.83 · Close at T+365 US$54.83
- +92.0%Entry US$4.35 · Close at T+365 US$8.35
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Hims & Hers Health, Inc. Hold (neutral), based on 13 analysts. Average price target: US$31.15.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,847 of 24,148 companies
35.5
score / 100
Value30
Quality41
FCF yld0.9%
Earn yld2.0%
EV/EBITDA47.9x
ROE-32%
Gross mgn74%
Net mgn5.5%
Debt/EBITDA7.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$27.72
Analyst consensus
13 analystsHold
US$23.00Target US$31.15(+12%)US$42.00
Income statement
RevenueUS$2.3B
Gross profitUS$1.7B74% margin
EBITDAUS$160.1M7% margin
Net incomeUS$128.4M-5.5% margin
Valuation
PER (forward)37.6x
P/Book20.0x
Beta2.43
Balance sheet & cash
Market capUS$6.5B
Total debtUS$1.1B
Free Cash FlowUS$57.4M
Debt / Equity477%
Profitability & ownership
ROE-32.0%
ROA-2.2%
% insiders4.9%
% institutions71.0%
Last declaration on 14 October 2026
Declarations627 total
3,461 shares@ US$29.060.0016% mcap0.8% of flowClass ASEC144:0001959173-26-007361
2,000 shares@ US$29.700.0009% mcap0.3% of flowClass ASEC144:0001959173-26-007182
3,461 shares@ US$29.170.0015% mcap0.8% of flowClass ASEC144:0001959173-26-007144
14,000 shares@ US$5.010.0011% mcap0.3% of flowClass A Common StockSEC:0001907056-26-000026:0
29,277 shares@ US$29.950.013% mcap4.1% of flowClass ASEC144:0001959173-26-007071
12,313 shares@ US$28.820.0053% mcap1.7% of flowClass ASEC144:0001959173-26-007029
6,236 shares@ US$27.860.0026% mcap1.3% of flowClass ASEC144:0001959173-26-007001
14,027 shares@ US$28.390.0059% mcap2.7% of flowClass ASEC144:0001959173-26-006962
7,954 shares@ US$28.390.0034% mcap5.8% of flowClass ASEC144:0001959173-26-006963
3,458 shares@ US$28.330.0015% mcap0.8% of flowClass A Common StockSEC:0001837817-26-000013:0
463,289 shares0Class A Common StockSEC:0001773751-26-000217:0
977,566 shares0Class A Common StockSEC:0001773751-26-000217:1
4,938 shares@ US$29.99420.0022% mcap0.7% of flowClass A Common StockSEC:0001907056-26-000022:1
4,938 shares@ US$5.010.0004% mcap0.1% of flowClass A Common StockSEC:0001907056-26-000022:0
25,111 shares@ US$27.550.010% mcap5.3% of flowClass ASEC144:0001959173-26-006194
16,773 shares@ US$27.850.0069% mcap39.6% of flowClass ASEC144:0001959173-26-006133
13,685 sharesClass A Common StockSEC:0001773751-26-000206:0
6,623 sharesClass A Common StockSEC:0001773751-26-000214:0
42,261 sharesClass A Common StockSEC:0001773751-26-000215:0
260 sharesClass A Common StockSEC:0001773751-26-000213:0
10,201 shares@ US$28.150.0043% mcap4.5% of flowClass A Common StockSEC:0001773751-26-000213:2
6,490 shares@ US$28.150.0027% mcap5.9% of flowClass A Common StockSEC:0001773751-26-000206:1
21,500 shares@ US$28.150.0090% mcap4.7% of flowClass A Common StockSEC:0001773751-26-000215:1
25,927 sharesClass A Common StockSEC:0001773751-26-000213:1
86,265 sharesClass A Common StockSEC:0001773751-26-000211:0
25 of 627 declarations
About Hims & Hers Health, Inc.
Hims & Hers Health, Inc. (NYSE: HIMS) is a US-listed consumer health and telehealth platform headquartered in San Francisco, California, in the United States. Founded in 2017 by Andrew Dudum, Hilary Coles, Jack Abraham, and Joe Spector at the venture studio Atomic, the company was built around a direct-to-consumer model aimed at making healthcare more convenient, more accessible, and more personalized. From its early roots as a digitally native brand, Hims & Hers has evolved into a multi-specialty care platform that connects customers with licensed healthcare professionals and a broader set of health and wellness products and services. ([investors.hims.com](https://investors.hims.com/news/news-details/2021/Hims--Hers-Appoints-Two-New-Board-Members/default.aspx?utm_source=openai))
The company’s core business spans several consumer healthcare categories, including sexual health, dermatology, mental health, hair loss, primary care, heart health, weight loss, and other wellness-related offerings. Its model combines telehealth consultations, clinician-led care pathways, prescription fulfillment where appropriate, and branded products delivered through a digital customer experience. This integrated approach is central to the company’s competitive positioning: Hims & Hers is not just a telehealth marketplace, but a brand-led care platform designed to improve engagement, adherence, and customer retention. Management has consistently emphasized personalization, simplicity, and affordability as key differentiators in a crowded and evolving digital health market. ([investors.hims.com](https://investors.hims.com/news/news-details/2021/Hims--Hers-Appoints-Two-New-Board-Members/default.aspx?utm_source=openai))
Read moreShow less
Geographically, the company first established scale in the United States and reports service availability across all 50 states and Washington, D.C. It has recently moved beyond a purely domestic story and is pursuing an international growth strategy. In 2026, Hims & Hers announced an agreement to acquire Eucalyptus, a transaction intended to accelerate its ambition to become a leading global consumer health platform. That move signals a broader long-term opportunity beyond the US market, while also increasing execution and regulatory complexity. ([investors.hims.com](https://investors.hims.com/news/news-details/2021/Hims--Hers-Appoints-Two-New-Board-Members/default.aspx?utm_source=openai))
Recent developments have reinforced the company’s growth narrative. In May 2026, Hims & Hers reported first-quarter 2026 revenue of approximately $608 million, subscriber growth to nearly 2.6 million, and an upward revision to full-year 2026 guidance. The company has also continued to expand its product portfolio, including women’s health, weight-loss solutions, multi-cancer early detection testing, and partner-based wellness benefits. For investors, the equity case is therefore anchored in a combination of rapid top-line growth, product expansion, brand strength, and a scalable digital distribution model, alongside the usual telehealth sector risks related to regulation, clinical scrutiny, and competitive intensity. ([investors.hims.com](https://investors.hims.com/news/news-details/2026/Hims--Hers-Health-Inc--Reports-First-Quarter-2026-Financial-Results/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
